Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",body mass,,RS:0000228,DA.PVG.1AV1-(D4Rat155-Spr),both,200 days to 120 days,14,,CMO:0001400,maximum body weight loss to initial body weight ratio,,,,12.5,%,0.9,3.3675,MMO:0000016,body weighing method,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69800,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",body mass,,RS:0000228,DA.PVG.1AV1-(D4Rat155-Spr),both,200 days to 120 days,24,,CMO:0001400,maximum body weight loss to initial body weight ratio,,,,10.6,%,1.1,5.3889,MMO:0000016,body weighing method,,0.0,,,,,pristane (150 ul) ,69806,pristane (150 ul) , 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0000228,DA.PVG.1AV1-(D4Rat155-Spr),both,0 days,12,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,25,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70197,Freund's incomplete adjuvant (200 ul) , 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000228,DA.PVG.1AV1-(D4Rat155-Spr),both,200 days to 120 days,24,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69719,pristane (150 ul) , 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000228,DA.PVG.1AV1-(D4Rat155-Spr),both,200 days to 120 days,14,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,100,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69712,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0000228,DA.PVG.1AV1-(D4Rat155-Spr),both,0 days,12,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,13.7,d,0.433,1.5,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70198,Freund's incomplete adjuvant (200 ul) , 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000228,DA.PVG.1AV1-(D4Rat155-Spr),both,200 days to 120 days,14,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,14.3,d,0.3,1.1225,MMO:0000163,in vivo visual assessment,,0.0,,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69780,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",joint integrity trait,,RS:0000228,DA.PVG.1AV1-(D4Rat155-Spr),both,200 days to 120 days,24,,CMO:0001450,post-insult time to onset of experimental arthritis,,,,12.5,d,0.5,2.4495,MMO:0000163,in vivo visual assessment,,0.0,,,,,pristane (150 ul) ,69787,pristane (150 ul) , 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",orosomucoid 1 amount,blood alpha-1-acid glycoprotein amount,RS:0000228,DA.PVG.1AV1-(D4Rat155-Spr),both,180 days to 120 days,14,,CMO:0001466,serum orosomucoid 1 level,,,,660,mg/l,,,MMO:0000439,radial immunodiffusion assay,,0.0,radial immunodiffusion assay,,,,type II collagen (500 ug) and Freund's incomplete adjuvant (100 ul) ,69759,type II collagen (500 ug) ,Freund's incomplete adjuvant (100 ul) 1162,"Backdahl L, et al., Arthritis Rheum 2003 Feb;48(2):551-9.",orosomucoid 1 amount,blood alpha-1-acid glycoprotein amount,RS:0000228,DA.PVG.1AV1-(D4Rat155-Spr),both,180 days to 120 days,24,,CMO:0001466,serum orosomucoid 1 level,,,,1060,mg/l,,,MMO:0000439,radial immunodiffusion assay,,0.0,radial immunodiffusion assay,,,,pristane (150 ul) ,69766,pristane (150 ul) ,